section name header

Indications

REMS

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

With initial use; incidence decreases with prolonged use

GI: fecal urgency, flatus with discharge, defecation, oily evacuation, oily spotting, fecal incontinence, HEPATOTOXICITY.

GU: nephrolithiasis, renal impairment/failure.

Interactions

Drug-Drug:

Availability

Route/Dosage

US Brand Names

Alli, Xenical

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: weight control agents

Pharmacologic Classification: lipase inhibitors

Pharmacokinetics

Absorption: Minimal systemic absorption.

Distribution: Action is local, within the GI tract.

Protein Binding: Minimally absorbed drug is >99% bound to plasma proteins.

Metabolism/Excretion: Major route is fecal elimination of unabsorbed drug.

Half-life: 1–2 hr.

Time/Action Profile

(effects on fecal fat)

ROUTEONSETPEAKDURATION
PO24–48 hrunknown48–72 hr

†Following discontinuation.

Patient/Family Teaching

Pronunciation

OR-li-stat